Daiichi Life Insurance Co. Ltd. Makes New Investment in Edwards Lifesciences Corporation $EW

Key Points

• Daiichi Life Insurance acquired 22,329 shares of Edwards Lifesciences in the second quarter, valued at approximately $2.02 million. Institutional investors collectively own 79.46% of the company.
• Analysts remain broadly positive, with 17 Buy ratings and six Holds contributing to a “Moderate Buy” consensus and an average price target of $100.27.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in EPS versus the $0.74 estimate and $1.74 billion in revenue, up 13.6% year over year. Shares recently opened at $89.89.

Daiichi Life Insurance Co. Ltd. acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 22,329 shares of the medical research company's stock, valued at approximately $2,020,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences during the first quarter worth approximately $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at $25,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences during the 4th quarter worth $26,000. RMG Wealth Management LLC bought a new position in Edwards Lifesciences during the 1st quarter worth $26,000. Finally, TrinityBridge Ltd acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $27,000. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Evercore reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Mizuho raised their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 15th. Citigroup boosted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. Barclays reaffirmed an "overweight" rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $89.89 on Monday. The company's 50 day moving average price is $89.21 and its two-hundred day moving average price is $84.68. The firm has a market capitalization of $51.76 billion, a P/E ratio of 51.66, a P/E/G ratio of 2.25 and a beta of 0.85. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business's quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the company's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,570 shares of company stock valued at $2,219,390 in the last three months. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source